Psilocybin

Vancouver, British Columbia, August 11, 2025 – Filament Health Corp. (OTC:FLHLF) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended June 30, 2025. “This quarter, we took deliberate steps to position Filament Health for long-term growth, including streamlining our public listings to reduce costs and increase operational efficiency. We advanced our clinical and licensing portfolio with two significant developments: securing an exclusive global license for intellectual property and data usage from a Phase 2 study of psilocybin as a treatment for cocaine use disorder, and receiving approval to initiate a Phase 2 trial of our botanical psilocybin drug candidate, PEX010, for the treatment of prolonged brief disorder in Sweden,” said Benjamin Lightburn, Chief Executive Officer and Co-Founder at Filament Health. “These achievements reflect our commitment to pioneering psychedelic drug development while managing our resources strategically, ensuring that we are well-positioned to continue delivering on our mission. The demand for botanical psychedelic treatments continues to grow as noted by the recent approval of PEX010 for compassionate use in Germany for administration to a patient suffering from treatment-resistant depression (TRD) - the EU’s first ever approval of psilocybin for compassionate use.” Q2 2025 Financial Highlights: - On May 28, 2025, the Company’s common shares shifted from the OTCQB Venture Market to the OTC Pink Limited Information tier, and its listing on the Frankfurt Stock Exchange was terminated. - On May 6, 2025, the Company held a Special Meeting for the voluntary delisting of its common shares from CBOE Canada, which was approved by shareholder vote, and the Company was delisted from the CBOE Canada Exchange as of May 21, 2025. - On April 9, 2025, the Company closed a financing of $961,275 further to the issuance of units, comprised of a secured convertible debenture of the company and a warrant. - Cash and cash equivalents of $679,972; - Cash used in operating activities of $592,136; and total revenues of $259,013. Q2 2025 Operational Highlights: - On June 17, 2025, the Company announced that it entered into an exclusive global license agreement with the University of Alabama at Birmingham for intellectual property related to a recently completed Phase 2 placebo-controlled clinical trial of psilocybin as a treatment for cocaine use disorder. - On June 11, 2025, the Company announced that the Swedish Ethical Review Authority and Swedish Medical Products Agency have authorized a double-blind Phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University, for the treatment of prolonged grief disorder. Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at www.filament.health and on X, Instagram, and LinkedIn. media@filament.health ir@filament.health Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. The forward-looking statements discussed in this press release may include, but are not limited to, information concerning the impact of the patent on the Company’s business and the ability of the Company to secure future patents. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. ‍

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLabs and continued that investment in 2025. This achievement reflects the impact of Psyence BioMed’s ongoing investment and collaboration, which continues to support PsyLabs’ development of scalable, compliant, and globally relevant psychedelic APIs. PsyLabs continues to push the boundaries of pharmaceutical innovation, with ongoing development aimed at further increasing purity levels to isolate standards. “This is a groundbreaking moment for our entire team on the ground who have put countless hours and effort into ensuring our naturally derived, sustainable input materials are extracted with the same caution, mindfulness, and care, all covering the GMP manufacturing processes,” said Cody Robyn Futeran, Head of Extraction Innovations and Business Development at PsyLabs. “I’m extremely proud of our team for receiving such outstanding results showing PsyLabs’ readiness to fulfil orders of safe-for-consumption medications across the world.” Building on this momentum, Tony Budden, CEO of PsyLabs, emphasized the broader impact of the achievement. "Achieving this milestone is a testament to our team's dedication and our state-of-the-art facilities," said Budden. "We are committed to refining our processes to achieve even higher purity levels, supporting the growing demand for high-quality psychedelic APIs." PsyLabs’ extraction division is currently expanding its chemistry production area to ensure it consistently meets the growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs, derived from both Iboga and Mushrooms. PsyLabs’ Ibogaine will be available to licensed research institutions and developers worldwide, ensuring a reliable and ethically sourced supply. About PsyLabs PsyLabs is a psychedelic Active Pharmaceutical Ingredient (API) development company, federally licensed to cultivate, extract, and export psilocybin mushrooms and other psychedelic compounds including psilocin, mescaline, ibogaine, and dimethyltryptamine (DMT) to legal medical and research markets. The company has successfully exported psilocybin products to Canada, the UK, Portugal, and Slovenia, and supplies purified extracts to its UK-based CMO partner. PsyLabs operates from an ISO 22000-certified facility audited by the British Standards Institution, ensuring the highest standards of safety and traceability. With a focus on natural compound purification, regulatory support, and global distribution, PsyLabs is expanding its product pipeline to include ibogaine and other next-generation psychedelics.www.psylabs.life About Psyence BioMed Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs, particularly in palliative care. The name ‘Psyence’ merges ‘psychedelics’ and ‘science,’ reflecting the company’s commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders. Learn more at www.psyencebiomed.com and on LinkedIn. Contact Information for Psyence Biomedical Ltd.Email: ir@psyencebiomed.com Media Inquiries: media@psyencebiomed.comGeneral Information: info@psyencebiomed.comPhone: +1 416-477-1708 Investor Contact:Michael KyddInvestor Relations Advisormichael@psyencebiomed.com Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning. Forward-looking statements in this communication include statements regarding PsyLabs and the creation of long-term shareholder value. These forward-looking statements are based on a number of assumptions, including continuing progress by PsyLabs and its business operations. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) delays in PsyLabs’ progress; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-284444) filed with the Securities and Exchange Commission (the “SEC”) on January 24, 2025 and other documents filed by Psyence BioMed from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements. The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.